5/17/2023 0 Comments Chimex inc“Glioma remains one of the highest areas of unmet need in oncology where even first-line radiation therapy, as well as temozolomide in eligible patients, is not meaningfully effective and subsequent therapies are considered palliative. “The tumor responses and safety profile we have observed with ONC201 in this devastating disease are compelling and I look forward to the possibility of accelerating its delivery to patients.” Patrick Wen, Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and professor of Neurology at Harvard Medical School. “Patients with H3 K27M-mutant glioma are in desperate need of better therapeutic alternatives,” said Dr. The final confirmatory data analysis is expected in 2021. Initial evaluation of data from the full 50-subject registration cohort, which remains subject to full maturation and confirmation by Blinded Independent Central Review (BICR), indicate a compelling and particularly durable single agent Overall Response Rate (ORR) of at least 20% as assessed by Response Assessment in Neuro-Oncology-High Grade Glioma (RANO-HGG). Patients with this mutation are considered grade IV by the World Health Organization, regardless of underlying histology or age. Compelling responses at this stage of disease are rare and lack durability. Recurrent pediatric patients, with cancer that carries the H3 K27M mutation, have an even worse prognosis with median overall survival of approximately four months. Recurrent glioma is a form of brain cancer with a particularly poor prognosis having a median overall survival of approximately eight months. ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. 08, 2021 (GLOBE NEWSWIRE) - Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Management to Host Conference Call at 8:30 a.m. Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million Metro station «Lenina sq.ONC201 Registrational Trial for Recurrent H3 K27M-mutant GliomaĬompelling Response Rates to Date Defined Regulatory Path to Registration How to get : Metro station «Ladozhskaya», taxi-bus № 397(92-А) to Conclusion of long-term contracts and storage of necessary for you products and materials in our storehouse.Īddress: 67-B, Kommuny str., Saint-Petersburg, 195030, Russia.Delivery of products in the storehouse at customer’s agreement.Free of charge catalogues of firms, technical documentation and materials on all products you are interested in.Individual approach, attentive attitude to customers and highly qualified personnel.The range of production is constantly enlarged taking into consideration the customer’s requests. Chemical reagents and analytical equipment fromīesides, we are always ready to deliver all necessary for you production from other firms on your request!Ĭhemical reagents and analytical devices are delivered to scientific-research institutes to firms, specialized in biotechnical and microbiological areas to beer brewing and cosmetics companies to analytical laboratories of various companies to quality control centers of production.Epoxy resins, blends, hardeners, accelerators, active diluents and another products. Welcome to the CHIMEX Limited corporate web site «CHIMEX Limited» - is the scientific-industrial firm, founded in 1991 г.
0 Comments
Leave a Reply. |